The move comes after President Donald Trump warned Big Pharma leaders that he would impose tariffs on them if they refuse to ...
At the four new sites, Lilly expects to create more than 3,000 jobs for engineers, scientists, operations personnel, and lab technicians.
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Tourmaline Bio (TRML – Research Report). The ...
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
DelveInsight's High Potency Active Pharmaceutical Ingredients Market Insights report provides the current and forecast market ...
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company ...
19h
Hosted on MSNEli Lilly to expand US pharma manufacturing with four new sitesEli Lilly has announced plans to expand its domestic medicine production in the US by establishing four new pharmaceutical ...
13h
Legit on MSNApple accused of greenwashing in US lawsuitA group of Apple Watch buyers have filed a lawsuit in Silicon Valley accusing the tech giant of exaggerating how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results